NCT04297280View on ClinicalTrials.gov

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

July 18, 2023

Study Completion Date

February 25, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sintilimab

a PD-1 immune check inhibitor

COMBINATION_PRODUCT

TACE

TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04297280 - TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter